We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seeking Clues to 10x Genomics (TXG) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect 10x Genomics (TXG - Free Report) to post quarterly loss of $0.32 per share in its upcoming report, which indicates a year-over-year increase of 22%. Revenues are expected to be $158.14 million, down 14% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 0.2% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Given this perspective, it's time to examine the average forecasts of specific 10x Genomics metrics that are routinely monitored and predicted by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Revenues- Consumables' of $128.51 million. The estimate suggests a change of -8.4% year over year.
Analysts' assessment points toward 'Revenues- Instruments' reaching $19.02 million. The estimate indicates a change of -50.5% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenues- Services' should arrive at $6.52 million. The estimate points to a change of +23.7% from the year-ago quarter.
Over the past month, 10x Genomics shares have recorded returns of -23.2% versus the Zacks S&P 500 composite's +4.2% change. Based on its Zacks Rank #3 (Hold), TXG will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Seeking Clues to 10x Genomics (TXG) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Wall Street analysts expect 10x Genomics (TXG - Free Report) to post quarterly loss of $0.32 per share in its upcoming report, which indicates a year-over-year increase of 22%. Revenues are expected to be $158.14 million, down 14% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 0.2% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Given this perspective, it's time to examine the average forecasts of specific 10x Genomics metrics that are routinely monitored and predicted by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Revenues- Consumables' of $128.51 million. The estimate suggests a change of -8.4% year over year.
Analysts' assessment points toward 'Revenues- Instruments' reaching $19.02 million. The estimate indicates a change of -50.5% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenues- Services' should arrive at $6.52 million. The estimate points to a change of +23.7% from the year-ago quarter.
View all Key Company Metrics for 10x Genomics here>>>
Over the past month, 10x Genomics shares have recorded returns of -23.2% versus the Zacks S&P 500 composite's +4.2% change. Based on its Zacks Rank #3 (Hold), TXG will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>